ArticleJCI insight2018

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Paola Cassis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.